Skip to main content

Cost-effective reimbursement analysis for medical technologies in Europe

Procedure coding, payment mechanism, reimbursement tariffs, policy, and HTA considerations in 34 EU countries

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Swedish MTP Council made positive recommendations for three spinal cord stimulation devices

Swedish Medical Technologies Product (MTP) Council evaluated products for spinal cord stimulation (SCS) as part of the Orderly introduction framework. This framework supports the national adoption of novel technologies via a staged process, including horizon scanning, selection of the method for evaluation, the decision on national collaboration, health economic evaluation by the Swedish Dental and Pharmaceutical Benefits Agency (TLV), and recommendations by the MTP Council to regions regarding the implementation of the technology and criteria for use.

The TLV considered the evaluation of five devices: Intellis (Medtronic), Proclaim 3660ANS (Abbott), WaveWriter Alpha (Boston Scientific), Omnia Senza IPG (Nevro), and Evoke (Saluda Medical). However, two companies (Nevro and Saluda Medical) have declined to participate in the evaluation. In late 2023, TLV completed health economic evaluations of three devices.

On March 26, 2024, the MTP Councill published the following recommendations to the regions:

  • Intellis, Proclaim, and WaveWriter devices can be used in all patients with neuropathic pain and insufficient effect of conventional treatment;
  • The patient selection for SCS should be coordinated nationally, and data about the effects of Intellis, Proclaim, and Wavewriter should be systematically collected;
  • Refrain from using Evoke and Omnia Senza.

See the full details in Swedish here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.